JihongLou Ph.D.

Associate

Washington + 1.202.879.3631

Jihong Lou represents innovative pharmaceutical companies in patent litigation involving small-molecule drugs, including cases arising under the Hatch-Waxman Act. Drawing from her years of experience as a former Federal Circuit law clerk, a patent agent, and a medicinal chemist and drug discovery project leader, Jihong applies her in-depth technical and legal experience in advising clients on a wide variety of intellectual property issues.

Jihong's practice focuses on intellectual property litigation and appeal, with a particular emphasis on patent litigation in the fields of pharmaceuticals and biotechnology. She also represents clients in post-grant proceedings before the United States Patent and Trademark Office. In addition to patent litigation and appeal, Jihong advises clients regarding patentability, validity, infringement, and freedom-to-operate issues and in due diligence evaluations. She also maintains an active pro bono practice. She has successfully represented a number of veterans in appeals before the United States Court of Appeals for Veterans Claims.

Prior to law school, Jihong was a project leader and associate research fellow in medicinal chemistry at Pfizer, where she worked on drug discovery projects in oncology, diabetes, ophthalmology, and viral disease therapeutic areas. In 2008 she embarked on a career in law by attending law school in the evenings while working as a patent agent at Jones Day. From 2013 to 2017, she served as a law clerk to the Honorable Alan D. Lourie on the United States Court of Appeals for the Federal Circuit.

Experience

  • SKI defends ITC and district court actions relating to five lithium-ion battery patentsSK Innovation Co., Ltd., a Korea-based technology leader in the energy industry and in the development of lithium-ion batteries for electric vehicles, retained Jones Day to defend it and its U.S. subsidiary, SK Battery America, Inc., in a patent infringement case involving five patents, filed in the District of Delaware by LG Chem, Ltd. and Toray Industries, Inc., as well as at the ITC involving four of the same five patents.
  • Sloan Kettering and Juno Therapeutics win over $1.1 billion after jury verdict and post-trial motions in patent dispute with Kite Pharma/Gilead involving CAR-T therapyOn behalf of patentee Sloan Kettering Institute and exclusive licensee Juno Therapeutics (a subsidiary of Celgene Corporation, a Bristol Myers Squibb company), Jones Day and co-counsel prevailed in a jury trial that spanned eight days and involved 22 witnesses, wherein the jury awarded our clients $752 million in compensation for the infringement of their patents by Kite Pharma, Inc. (a Gilead Sciences, Inc. company) through the making and selling of its infringing CAR-T therapy, YESCARTA®.
  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • Celgene successfully blocks PTAB institution of IPR involving REVLIMID®Jones Day represented Celgene Corporation in successfully blocking institution of inter partes review ("IPR") of a patent covering the use of Celgene's REVLIMID® brand drug to treat multiple myeloma.
  • Celgene successfully blocks institution of inter partes review on three patents listed in the Orange Book for its blockbuster REVLIMID® productJones Day represented Celgene Corporation in successfully blocking institution of inter partes review ("IPR") of three patents covering the use of Celgene's REVLIMID® brand drug to treat myelodysplastic syndrome (“MDS”).
  • Celgene asserts its REVLIMID® patents against Apotex Inc. under Hatch-Waxman ActJones Day is representing Celgene Corporation as a plaintiff to enforce its patents against Apotex Inc. in a Hatch-Waxman litigation matter involving Apotex’s proposed generic versions of REVLIMID®, which is prescribed for treating multiple myeloma and other cancers.
  • Celgene asserts its REVLIMID® patents against Sun Pharma under Hatch-Waxman ActJones Day is representing Celgene Corporation as a plaintiff to enforce its patents against Sun Pharma Global FZE, Sun Pharma Global Inc., Sun Pharmaceutical Industries, Inc., and Sun Pharmaceutical Industries Limited in a Hatch-Waxman litigation matter involving Sun’s proposed generic versions of REVLIMID®, which is prescribed for treating multiple myeloma and other cancers.
  • Celgene enforces its REVLIMID® patents against Lotus Pharmaceutical under Hatch-Waxman ActJones Day is representing Celgene Corporation as a plaintiff to enforce its patents against Lotus Pharmaceutical Co., Ltd. in Hatch-Waxman litigations involving proposed generic versions of REVLIMID®, which is prescribed for treating multiple myeloma and other cancers.
  • Celgene asserts its REVLIMID® patents against Cipla under Hatch-Waxman ActJones Day is representing Celgene Corporation as a plaintiff to enforce its patents against Cipla Limited in Hatch-Waxman litigation matters involving Cipla’s proposed generic versions of REVLIMID®, which is prescribed for treating multiple myeloma and other cancers.
  • Celgene asserts its REVLIMID® patents against Dr. Reddy’s Laboratories under Hatch-Waxman ActJones Day is representing Celgene Corporation as a plaintiff to enforce its patents against Dr. Reddy's Laboratories in several Hatch-Waxman litigation matters involving DRL's proposed generic versions of REVLIMID®, which is prescribed for treating multiple myeloma and other cancers.
  • Celgene enforces its Revlimid® patents against Zydus Pharmaceuticals under Hatch-Waxman ActJones Day is representing Celgene Corporation in a patent litigation against Zydus Pharmaceuticals and Cadila Healthcare over Revlimid®, Celgene's blockbuster drug for treating multiple myeloma and other cancers.
  • Celgene appeals decision from Opposition Division to revoke lenalidimide European patentJones Day represents Celgene Corporation in the appeal of a decision in opposition proceedings against two generic companies opposing a Celgene European patent covering the polymorphs of lenalidimide.
  • Celgene obtains dismissal with prejudice of patent infringement claims involving its Vidaza® brand drugJones Day represented Celgene Corporation in a patent infringement lawsuit involving the company’s Vidaza® brand drug that was filed by IVAX LLC in the Southern District of Florida.
  • Celgene acquires Abraxis BioScience for $2.9 billionJones Day advised Celgene Corporation in its $2.9 billion merger with Abraxis BioScience Inc.
  • Additional Publications

    • 2011
      Identification of Novel Pyrrolopyrazoles as Protein Kinase C beta II Inhibitors, coauthor, Bioorganic & Medicinal Chemistry Letters, 21(1), 584
    • 2009
      Pyridones as Glucokinase Activators: Identification of a Unique Metabolic Liability of the 4-Sulfonyl-2-Pyridone Heterocycle, coauthor, Bioorganic & Medicinal Chemistry Letters, 19(12), 3247

    Publications Prior to Jones Day

    2008  
    Steady-State and Pre-Steady-State Kinetic Evaluation of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 3CLpro Cysteine Protease: Development of an Ion-Pair Model for Catalysis, coauthor, Biochemistry, 47(8), 2617

    2000  
    The Binding of Cocaine to Cyclodextrins, coauthor, Bioorganic & Medicinal Chemistry Letters, 10(17), 1931

    2000  
    Synthetic Retinals: Convenient Probes of Rhodopsin and Visual Transduction Process, coauthor, Methods in Enzymology, 315, 219

    1999  
    Enantioselective Binding of an 11-cis-Locked Cyclopropyl Retinal. The Conformation of Retinal in Bovine Rhodopsin, coauthor, Organic Letters, 1(1), 51

    1999  
    Coherent Anti-Stokes Vibrational Raman Spectra of Artificial Rhodopsin Pigments Containing Ring Structures Blocking 11-cis Isomerization, coauthor, Journal of Molecular Structure, 478(1-3), 107

    1998  
    Vibrational Spectroscopy of a Picosecond, Structurally Restricted Intermediate Containing a 7-Membered Ring in the Room Temperature Photo-Reaction of an Artificial Rhodopsin, coauthor, Journal of the American Chemical Society, 120(15), 3739

    1998  
    Solving Challenging Bioorganic Problems by Exciton Coupled CD, coauthor, Pure & Applied Chemistry, 70(2), 377

    1997  
    Absolute Sense of Twist of the C-12/13 Bond of the Retinal Chromophore in Bovine Rhodopsin Based on Coupled CD of 11,12-Dihydroretinal Analogs, coauthor, Angew. Chem. Int. Ed. Engl., 36(19), 2089

    1997  
    Partial Agonist Activity of 11-cis-Retinal in Rhodopsin Mutants, coauthor, Journal of Biological Chemistry, 272(37), 23081

    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.